BO 112

Drug Profile

BO 112

Alternative Names: BO-112

Latest Information Update: 17 Jul 2017

Price : $50

At a glance

  • Originator Bioncotech Therapeutics
  • Class Antineoplastics
  • Mechanism of Action IFIH1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 17 Jul 2017 3251330- Added info to KDM; updated AE section and updated MoA
  • 02 Jun 2017 Adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top